Sun Pharma to Close Detroit Manufacturing Facility of Caraco Pharmaceutical Laboratories

By Pharma News - DCAT Publisher

May 2, 2014

Sun Pharmaceutical Industries Ltd announced that, as a part of its manufacturing consolidation in the US, it will cease manufacturing operations and close the Detroit facility of Caraco Pharmaceutical Laboratories, a subsidiary of Sun Pharma USA, the US arm of the Mumbai-based Sun Pharmaceutical Industries. Ltd.

Sun Pharma has notified the Workforce Development Agency for the State of Michigan regarding its decision to cease manufacturing operations and has provided the requisite written notice of the facility closure to the employee union and all affected employees.The rest of the employees are continuing through mutually consented arrangements

Sun Pharma has undertaken necessary measures to ensure business continuity of the products being manufactured at this facility. The manufacturing of these products is being transferred to other units and all necessary steps have been taken to avoid market shortage, said the company.

Earlier this year, Caraco issued a voluntary recall of select bottles of metformin.

In 2009, US marshals, at the request of FDA, seized drug products and ingredients manufactured by Caraco at the Detroit facilities as well as two other facilities in Michigan at Farmington Hills and Wixom. The action followed Caraco's failure to meet current good manufacturing practice (cGMP) requirements and the issuance of several voluntary recalls. Caraco corrected the violations and resumed operations in 2012 at the Detroit facility.

Source: Sun Pharmaceutical Industries